CAR T-cell Therapy in Patients With Renal Dysfunction

This study is examining the safety and outcomes of CAR T-cell therapy (an advanced immune cell treatment) in patients with blood cancers — including multiple myeloma, leukemia, or lymphoma — who also have reduced kidney function. CAR T-cell therapy is typically given primarily to patients with normal kidney function, and this study aims to understand if it can be safely offered to those with kidney problems. **You may be eligible if...** - You are receiving CAR T-cell therapy for multiple myeloma, leukemia, or lymphoma - Your kidney function is reduced (eGFR below 60 mL/min/1.73m²) - You have adequate bone marrow function to receive the preparatory chemotherapy - Your general health is reasonably good (ECOG 0–2) **You may NOT be eligible if...** - You have significant brain or nervous system disorders - You have an uncontrolled active infection or serious concurrent illness - You are on high-dose steroids (more than 20 mg prednisone per day) within 72 hours before your CAR T-cell infusion Talk to your doctor to see if this trial is right for you.